JAK2 Mutation and Additional Thrombophilic Markers Predispose to Thrombosis in Myeloproliferative Diseases with Thrombocythemia

OBJECTIVES: Bleeding and thrombotic events are common complications symptoms in myeloproliferative diseases with thrombocythemia (MPD-T). The increased platelet count need not be the only cause of them. In the current study we have evaluated prospectively collected data of 421 Czech patients from an international registry of patients treated with anagrelide (ANG) with the aim to check whether JAK2 V617F mutation or additional thrombophilic states predispose to thrombosis in MPD-T.